Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;3(1):3-10.
doi: 10.4103/2229-516X.112229.

Recent advances in antibacterial drugs

Jaswant Rai  1 , Gurpreet Kaur Randhawa, Mandeep Kaur
Affiliations

Recent advances in antibacterial drugs

Jaswant Rai et al. Int J Appl Basic Med Res. 2013 Jan.

Abstract

The incidence of antimicrobial resistance is on continued rise with a threat to return to the "pre-antibiotic" era. This has led to emergence of such bacterial infections which are essentially untreatable by the current armamentarium of available treatment options. Various efforts have been made to develop the newer antimicrobials with novel modes of action which can act against these multi-drug resistant strains. This review aims to focus on these newly available and investigational antibacterials approved after year 2000, their mechanism of actions/resistance, and spectrum of activity and their phases of clinical trials. Newer unexploited targets and strategies for the next generation of antimicrobial drugs for combating the drug resistance and emerging pathogens in the 21(st) century have also been reviewed in the present article.

Keywords: Biopotentiators; clostridium difficile infection; doripenem; pleuromutilin; virulence inhibitors.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Mechanism of action of ketolide that overcome resistance
See this image and copyright information in PMC

References

    1. Birkett D, Brøsen K, Cascorbi I, Gustafsson LL, Maxwell S, Rago L, et al. Clinical pharmacology in research, teaching and health care. Basic Clin Pharmacol Toxicol. 2010;107:531–59. - PubMed
    1. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology. 2010;156:3354–59. - PubMed
    1. Nordqvist C. Dificid (fidaxomicin) Approved for Clostridium difficile-associated diarrhea. [Last accessed on 2012 Jan 12]. Available from: http://www.medicalnewstoday.com/articles/226796.php .
    1. Poxton IR. Fidaxomicin: A new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infection. Future Microbiol. 2010;5:539–48. - PubMed
    1. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:3398–407. - PMC - PubMed